This is available for registered delegates and pay-to-view. Please login to watch. Press watch now if you're a registered delegate or would like to purchase the event.Watch Now
You can now purchase the video on a pay-to-view access if you missed the event. To purchase, please first ensure you are logged into your MyBIR portal. If you do not already have a MyBIR profile, please create one first. You can then click on the 'watch now' button on the video page to purchase access to the event.
BIR plan 1 members £195
BIR plan 2 members and trainees £145
BIR retired and student members £75
Non members £300
* VAT added at check out where applicable
The role of radionuclide theragnostic in prostate cancer is expanding. Current evidence supports PSMA PET-CT as an essential procedure for imaging prostate cancer patients, especially in the setting of recurrent cancer. Radiolabelled PSMA-PET-CT is a useful diagnostic and clinical decision-making tool in prostate cancer. Several national and international guidelines have a recommendation on its appropriate use. Radiolabelled PSMA therapies have shown good response and prolonged survival with limited adverse events. The results from the VISION trial are encouraging. A multidisciplinary approach and relevant knowledge transfer are essential for the best use of radiolabelled procedures in prostate cancer. National and International faculty aim to share their experience and discuss practical issues related to diagnostic and therapeutic applications in this true masterclass.
6 CPD points
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.